Cell Culture Market, By Product (Consumables, Instruments), By Application (Biopharmaceutical Production, Tissue Culture & Engineering, Toxicity Testing, Drug Development, Cell & Gene Therapy, and Others), By End User (Biopharmaceutical Companies, Hospitals & Diagnostic Laboratories, CMO & CRO, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Mar 2024

Code : CMI116

Pages :160

Formats :

Excel and PDF

Industry : Biotechnology

Regional Analysis

Cell Culture Market Regional Insights

To learn more about this report, Request sample copy

North America has established itself as the leading region in the global cell culture market and is expected to hold 39.7% of the market share in 2024. The presence of top pharmaceutical and biotechnology companies in countries like the U.S. has provided a major boost. There is a strong focus on R&D activities related to cell-based research by both private players as well as government institutes. This has led to a massive demand for cell culture equipment, media, and reagents as all new drug development processes now involve extensive cell-based testing. The cell therapy industry is also witnessing rapid growth in the U.S. due to efforts by companies developing new treatment options for chronic diseases. Many global players have set up their cell therapy research centers in North America to gain from the business-friendly environment and access to the talent pool. As more therapies reach the market in the coming years, the North American cell culture market is expected to further strengthen its dominant position.

The Asia Pacific region has emerged as the fastest-growing market for cell culture over the last five years. China, in particular, has emerged as a global force in pharmaceuticals and biologics, with the government focusing on building a robust healthcare ecosystem. Aggressive investments are being made to ramp up domestic R&D and manufacturing capabilities. Countries such as China, India, South Korea, and Singapore are offering attractive incentives to global players to set up facilities. This has led to a surge in infrastructure development for cell-based research. Additionally, the lower costs have prompted many global corporations to outsource certain testing activities to the region. Many biotech startups are also mushrooming with access to risk capital. With its massive population and growing healthcare needs, Asia Pacific's cell culture market is all set to witness exponential growth going forward to meet both the domestic and global demand.